* Immunomedics Inc., of Morris Plains, N.J., received clearance fromthe European Commission to market CEA-Scan (arcitumomab) fordetection of colorectal cancer in the European Union's 15 countries.The diagnostic is approved in the U.S. and is being marketed byMallinckrodt Group Inc., of St. Louis. CEA-Scan combines aradioisotope with an antibody fragment to carcinoembryonic antigen(CEA), which is expressed in numerous cancers. The company alsosaid LeukoScan, a radioisotope combined with an antibody fragmentto granulocytes, achieved positive results in a Phase III trial fordetecting which patients with atypical acute appendicitis requiredsurgery.
* PathoGenesis Corp., of Seattle, completed two double-blind,placebo-controlled Phase III trials of TOBI, a form of tobramycindelivered by inhaler, for treatment of lung infections in cystic fibrosispatients. Results are expected in the first quarter of 1997 and thecompany said it plans to file a new drug application with the FDA bythe end of the second quarter of 1997.
(c) 1997 American Health Consultants. All rights reserved.